Marta Flisiak-Jackiewicz

Dr. Marta Flisiak-Jackiewicz


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MFMarta Flisiak-Jackiewicz
Marta Flisiak-Jackiewicz
ABAnna Bobrus-Chociej
Anna Bobrus-Chociej
NWNatalia Wasilewska
Natalia Wasilewska
DLDariusz M. Lebensztejn
Dariusz M. Lebensztejn
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which predispose to more serious hepatic conditions. It ranges from simple liver steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis, and even end-stage liver disease. Since obesity became one of the most important health concerns wordwide, a considerable increase in the prevalance of NAFLD and other metabolic implications has been observed, both in adults and children. Due to the coexistence of visceral obesity, insulin resistance, dyslipidemia, NAFLD is considered to be the hepatic manifestation of metabolic syndrome (MetS). These relationships between NAFLD and MetS led to the set up in adults of a new term combining both of these conditions, called metabolic dysfunction-associated fatty liver disease (MAFLD). Based on these findings, we propose a set of criteria, which may be useful to diagnose MAFLD in children and adolescents.

3 January 2017 in Liver International
Verified
Journal Article
Closed access
Robert FlisiakRobert Flisiak
Robert Flisiak
JPJoanna Pogorzelska
Joanna Pogorzelska
MFMarta Flisiak-Jackiewicz
Marta Flisiak-Jackiewicz

1 January 2019 in Clinical and Experimental Hepatology
Verified
Journal Article
Open access
MFMarta Flisiak-Jackiewicz
Marta Flisiak-Jackiewicz
DLDariusz Marek Lebensztejn
Dariusz Marek Lebensztejn
Nonalcoholic fatty liver disease (NAFLD) represents the most common cause of chronic liver disease. Increasing prevalence of NAFLD in children may be the cause of unfavorable metabolic implications and development of end stage liver disease. NAFLD is a “multiple-hit” disease mediated by...

26 April 2018 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MFMarta Flisiak-Jackiewicz
Marta Flisiak-Jackiewicz
ABAnna Bobrus-Chociej
Anna Bobrus-Chociej
ETEugeniusz Tarasów
Eugeniusz Tarasów
MWMałgorzata Wojtkowska
Małgorzata Wojtkowska
IBIrena Białokoz-Kalinowska
Irena Białokoz-Kalinowska
DLDariusz Marek Lebensztejn
Dariusz Marek Lebensztejn
Introduction. Interleukin-18 (IL-18) is a proinflammatory cytokine associated with metabolic syndrome (MS). Nonalcoholic fatty liver disease (NAFLD) can be recognized as a feature of MS.Material and Methods. Serum IL-18 concentration was evaluated in serum of 108 obese children, determined with ELISA, and referred to degree of liver steatosis in USG or total intrahepatic lipid content assessed by magnetic resonance proton spectroscopy (1HMRS).Results. Fatty liver was confirmed in 89 children with USG and in 72 with1HMRS. IL-18 concentration demonstrated significantly higher values in patients than in controls. Significant correlations between IL-18 and ALT, GGT, triglycerides, hsCRP, and the degree of liver steatosis were demonstrated. NAFLD children had significantly higher level of IL-18, ALT, GGT, HOMA-IR, waist circumference, and total lipids content in1HMRS than other obese children. IL-18 level was also significantly higher in obese children with advanced liver steatosis. Measurement of serum IL-18 showed ability to differentiate children with fatty liver from those without steatosis.Conclusion. Elevated serum IL-18 concentration and its correlation with hepatocyte injury, systemic inflammation, and degree of liver steatosis support role in NAFLD pathomechanism. IL-18 can be considered to play a role in predicting advanced liver steatosis and fatty liver in obese children.

1 September 2019 in Advances in Medical Sciences
Verified
Journal Article
Closed access
MFMarta Flisiak-Jackiewicz
Marta Flisiak-Jackiewicz
ABAnna Bobrus-Chociej
Anna Bobrus-Chociej
NWNatalia Wasilewska
Natalia Wasilewska
ETEugeniusz Tarasow
Eugeniusz Tarasow
MWMalgorzata Wojtkowska
Malgorzata Wojtkowska
DLDariusz Marek Lebensztejn
Dariusz Marek Lebensztejn

30 June 2015 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
MFMarta Flisiak-Jackiewicz
Marta Flisiak-Jackiewicz
DLDariusz Lebensztejn
Dariusz Lebensztejn
Robert FlisiakRobert Flisiak
Robert Flisiak
(2015). Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs: Vol. 24, No. 9, pp. 1229-1239.